Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts
Portfolio Pulse from Benzinga Insights
In the past three months, 6 analysts have provided ratings for Ligand Pharmaceuticals (NASDAQ:LGND), ranging from bullish to bearish. The average 12-month price target is $132.83, with a high of $144.00 and a low of $95.00. Recent ratings include 'Outperform' and 'Buy' from various analysts, with some raising their price targets.
July 30, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ligand Pharmaceuticals (NASDAQ:LGND) has received mixed ratings from 6 analysts over the past three months, with an average 12-month price target of $132.83. Recent ratings include 'Outperform' and 'Buy', with some analysts raising their price targets.
The majority of analysts have a positive outlook on LGND, with recent ratings including 'Outperform' and 'Buy'. The average price target has slightly increased, indicating a generally optimistic view on the stock's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100